Monopar Therapeutics (MNPR) Exchange Rate Effect (2018 - 2025)
Monopar Therapeutics (MNPR) posted Exchange Rate Effect of $99495.0 for Q4 2025, up 26361.44% sequentially from $376.0 in Q3 2025, and up 2716.22% YoY from $3532.9 in Q4 2024.
Powered by 
Analysis
Monopar Therapeutics (MNPR) Exchange Rate Effect (2018 - 2025) Analysis & Trends
Monopar Therapeutics has reported Exchange Rate Effect for 8 years, with the latest figure at $99495.0 in Q4 2025.
- Quarterly Exchange Rate Effect rose 2716.22% year-over-year to $99495.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $97266.0 (up 19589.47% YoY) and the FY2025 annual result came in at $97266.0, up 19589.47% from the prior year.
- Exchange Rate Effect rose to $99495.0 in Q4 2025 per MNPR's latest filing, from $376.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $99495.0 in Q4 2025 and troughed at -$48687.0 in Q4 2022.
- A 5-year average of $4105.5 and a median of -$23.0 in 2021 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 313750.0% in 2022, down 2556.46% in 2022.
- Over 5 years, Exchange Rate Effect stood at $1982.0 in 2021, then slumped by 2556.46% to -$48687.0 in 2022, then surged by 82.84% to -$8357.0 in 2023, then soared by 54.49% to -$3803.0 in 2024, then soared by 2716.22% to $99495.0 in 2025.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $99495.0, $376.0, and -$2551.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Monopar Therapeutics | 1.01 Bn | 954.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 99,495.00 |
| Sep 30, 2025 | 376.00 |
| Jun 30, 2025 | -2,551.00 |
| Mar 31, 2025 | -54.00 |
| Dec 31, 2024 | -3,803.00 |
| Sep 30, 2024 | 4,457.00 |
| Jun 30, 2024 | 1,492.00 |
| Mar 31, 2024 | -1,652.00 |
| Dec 31, 2023 | -8,357.00 |
| Sep 30, 2023 | 6,758.00 |
| Jun 30, 2023 | -4,354.00 |
| Mar 31, 2023 | -10,843.00 |
| Dec 31, 2022 | -48,687.00 |
| Sep 30, 2022 | 25,108.00 |
| Jun 30, 2022 | 20,760.00 |
| Mar 31, 2022 | -659.00 |
| Dec 31, 2021 | 1,982.00 |
| Sep 30, 2021 | 8.00 |
| Jun 30, 2021 | -140.00 |
| Mar 31, 2021 | 2,774.00 |